USPTO serial 79404951
MULTIGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 24, 2026
- Examiner
- SWEENEY, MOLLY B
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MULTIGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jessica S. Sachs
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.100 Bloomfield Hills ParkwaySuite 200Bloomfield Hills, MI 48034Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substances, namely, antibodies for stabilization of proteins, all the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; chimeric proteins to measure, test and develop compounds and ligands binding to G protein-coupled receptors (GPCRs); none of the foregoing for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies | ACTIVE | — |
| 005 | chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteins, namely, small molecules and antibodies for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; veterinary products, namely, antigens and reagents for use in oncology and immunology and for inflammatory, infection, gastro-intestinal, cardiovascular, pulmonary, neurological, metabolic, systemic, gynecological, urological, dermatological, and musculo-skeletal treatment and treatment of orphan diseases; none of the foregoing for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies | ACTIVE | — |
| 035 | Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management; none of the foregoing services for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies | ACTIVE | — |
| 042 | Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines; none of the foregoing services for vitamin supplements, for vitamin supplements or generic pharmaceuticals dispensed by prescription, or for vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Confo Therapeutics N.V.
- Other trademarks owned by Confo Therapeutics NV
- Other trademarks owned by Confo Therapeutics NV
- Other trademarks owned by Confo Therapeutics NV
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named MULTIGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 17, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 31, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 31, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 28, 2026 | IROP | IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB | — |
| Jul 13, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 12, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 24, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 24, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 24, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 29, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 28, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 14, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 13, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 5, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 5, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 5, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 27, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 27, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 27, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 12, 2025 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Jun 11, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 22, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 14, 2025 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Feb 6, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 6, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 31, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 1, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 31, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 30, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 27, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 27, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 26, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |